JPMorgan analyst Eric Joseph raised the firm’s price target on PTC Therapeutics (PTCT) to $78 from $72 and keeps an Overweight rating on the ...

Citi analyst Geoff Meacham raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $46 and keeps a Sell rating on the shares ...

PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...

Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from ...

Bank of America upgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from an underperform rating to a neutral ...

Arizona State Retirement System grew its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 1.1% in the 4th quarter, according to its most recent disclosure with the SEC. The ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: ...

PTC Therapeutics has recently undergone significant restructuring under the leadership of CEO Dr. Klein. The company has reduced its workforce by approximately 25% and implemented measures to ...

PTC Therapeutics Inc (NASDAQ:PTCT) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of PTC Therapeutics (NasdaqGS:PTCT) with a Sector Perform ...

Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Underperform to Neutral. As of March 5, 2025, the average one-year price ...

PTC Therapeutics has recently undergone significant restructuring under the leadership of CEO Dr. Klein. The company has reduced its workforce by approximately 25% and implemented measures to lower ...